Product References
Non-canonical Wnt/Ca2+ signaling is essential to promote self-renewal and proliferation in colon cancer stem cells.
Frontiers in oncology
Sarabia-Sánchez MA,Moreno-Londoño AP,Castañeda-Patlán MC,Alvarado-Ortiz E,Martínez-Morales JC,Robles-Flores M
Published figure using CD44var (v6) monoclonal antibody (Product # BMS125) in Flow Cytometry
Tue Mar 28 00:00:00 EDT 2023
ILC1 drive intestinal epithelial and matrix remodelling.
Nature materials
Jowett GM,Norman MDA,Yu TTL,Rosell Arévalo P,Hoogland D,Lust ST,Read E,Hamrud E,Walters NJ,Niazi U,Chung MWH,Marciano D,Omer OS,Zabinski T,Danovi D,Lord GM,Hilborn J,Evans ND,Dreiss CA,Bozec L,Oommen OP,Lorenz CD,da Silva RMP,Neves JF,Gentleman E
BMS125 was used in Immunocytochemistry-immunoflourescence to develop gut organoid cocultures with type-1 innate lymphoid cells (ILC1) to dissect the impact of their accumulation in inflamed intestines.
Mon Feb 01 00:00:00 EST 2021
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida).
Breast cancer research and treatment
Goldstein LJ,Mansutti M,Levy C,Chang JC,Henry S,Fernandez-Perez I,Prausovà J,Staroslawska E,Viale G,Butler B,McCanna S,Ruffini PA,Wicha MS,Schott AF
BMS125 was used in Immunohistochemistry to report the results of a phase 2 randomized, double-blind study [fRida trial (NCT02370238)] evaluating the safety and efficacy of reparixin plus paclitaxel vs. placebo plus paclitaxel in untreated metastatic triple-negative breast cancer.
Mon Nov 01 00:00:00 EDT 2021
PDX-derived organoids model in vivo drug response and secrete biomarkers.
JCI insight
Huang L,Bockorny B,Paul I,Akshinthala D,Frappart PO,Gandarilla O,Bose A,Sanchez-Gonzalez V,Rouse EE,Lehoux SD,Pandell N,Lim CM,Clohessy JG,Grossman J,Gonzalez R,Del Pino SP,Daaboul G,Sawhney MS,Freedman SD,Kleger A,Cummings RD,Emili A,Muthuswamy LB,Hidalgo M,Muthuswamy SK
BMS125 was used in Western Blotting to show organoid cultures can model in vivo drug responses and be used to discover clinically actionable serologic biomarkers.
Thu Nov 05 00:00:00 EST 2020
PDX-derived organoids model in vivo drug response and secrete biomarkers.
JCI insight
Huang L,Bockorny B,Paul I,Akshinthala D,Frappart PO,Gandarilla O,Bose A,Sanchez-Gonzalez V,Rouse EE,Lehoux SD,Pandell N,Lim CM,Clohessy JG,Grossman J,Gonzalez R,Del Pino SP,Daaboul G,Sawhney MS,Freedman SD,Kleger A,Cummings RD,Emili A,Muthuswamy LB,Hidalgo M,Muthuswamy SK
BMS125 was used in Western Blotting to show organoid cultures can model in vivo drug responses and be used to discover clinically actionable serologic biomarkers.
Thu Nov 05 00:00:00 EST 2020
CD44 alternative splicing and hnRNP A1 expression are associated with the metastasis of breast cancer.
Oncology reports
Loh TJ,Moon H,Cho S,Jang H,Liu YC,Tai H,Jung DW,Williams DR,Kim HR,Shin MG,Liao DJ,Zhou J,Shi W,Zheng X,Shen H
BMS125 was used in Western Blotting to study the effects of the knockdown of hnRNP A1 on the splicing of CD44 in breast cancer cells.
Tue Sep 01 00:00:00 EDT 2015
The Ser/Thr kinase MAP4K4 drives c-Met-induced motility and invasiveness in a cell-based model of SHH medulloblastoma.
SpringerPlus
Santhana Kumar K,Tripolitsioti D,Ma M,Grählert J,Egli KB,Fiaschetti G,Shalaby T,Grotzer MA,Baumgartner M
Published figure using CD44var (v6) monoclonal antibody (Product # BMS125) in Flow Cytometry
Tue Jan 27 00:00:00 EST 2015
The Ser/Thr kinase MAP4K4 drives c-Met-induced motility and invasiveness in a cell-based model of SHH medulloblastoma.
SpringerPlus
Santhana Kumar K,Tripolitsioti D,Ma M,Grählert J,Egli KB,Fiaschetti G,Shalaby T,Grotzer MA,Baumgartner M
Published figure using CD44var (v6) monoclonal antibody (Product # BMS125) in Flow Cytometry
Tue Jan 27 00:00:00 EST 2015
The Ser/Thr kinase MAP4K4 drives c-Met-induced motility and invasiveness in a cell-based model of SHH medulloblastoma.
SpringerPlus
Santhana Kumar K,Tripolitsioti D,Ma M,Grählert J,Egli KB,Fiaschetti G,Shalaby T,Grotzer MA,Baumgartner M
Published figure using CD44var (v6) monoclonal antibody (Product # BMS125) in Flow Cytometry
Tue Jan 27 00:00:00 EST 2015
The Ser/Thr kinase MAP4K4 drives c-Met-induced motility and invasiveness in a cell-based model of SHH medulloblastoma.
SpringerPlus
Santhana Kumar K,Tripolitsioti D,Ma M,Grählert J,Egli KB,Fiaschetti G,Shalaby T,Grotzer MA,Baumgartner M
Published figure using CD44var (v6) monoclonal antibody (Product # BMS125) in Flow Cytometry
Tue Jan 27 00:00:00 EST 2015
Stem cell CD44v isoforms promote intestinal cancer formation in Apc(min) mice downstream of Wnt signaling.
Oncogene
Zeilstra J,Joosten SP,van Andel H,Tolg C,Berns A,Snoek M,van de Wetering M,Spaargaren M,Clevers H,Pals ST
BMS125 was used in Immunohistochemistry to identify CD44v as component of the ISCs program critical for tumor initiation, and as potential treatment target in CRC.
Thu Jan 30 00:00:00 EST 2014
CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma.
Blood
Casucci M,Nicolis di Robilant B,Falcone L,Camisa B,Norelli M,Genovese P,Gentner B,Gullotta F,Ponzoni M,Bernardi M,Marcatti M,Saudemont A,Bordignon C,Savoldo B,Ciceri F,Naldini L,Dotti G,Bonini C,Bondanza A
BMS125 was used in Immunohistochemistry to study the effects of silencing CD44 isoform variant 6 on the engraftment of acute myeloid leukaemia and multiple myeloma cells in immunocompromised mice.
Thu Nov 14 00:00:00 EST 2013
Near-infrared fluorescence molecular imaging of ductal carcinoma in situ with CD44v6-specific antibodies in mice: a preclinical study.
Molecular imaging and biology
Vermeulen JF,van Brussel AS,Adams A,Mali WP,van der Wall E,van Diest PJ,Derksen PW
Published figure using CD44var (v6) monoclonal antibody (Product # BMS125) in Immunohistochemistry
Sat Jun 01 00:00:00 EDT 2013
Differential expression of growth factor receptors and membrane-bound tumor markers for imaging in male and female breast cancer.
PloS one
Vermeulen JF,Kornegoor R,van der Wall E,van der Groep P,van Diest PJ
BMS125 was used in Immunohistochemistry to investigate expression profiles of growth factor receptors and membrane-bound tumour markers in male breast cancer and gynecomastia, in comparison with female breast cancer.
Tue Jul 02 00:00:00 EDT 2013
Immunophenotyping invasive breast cancer: paving the road for molecular imaging.
BMC cancer
Vermeulen JF,van Brussel AS,van der Groep P,Morsink FH,Bult P,van der Wall E,van Diest PJ
Published figure using CD44var (v6) monoclonal antibody (Product # BMS125) in Immunofluorescence
Wed Jun 13 00:00:00 EDT 2012
Clinicopathological associations of CD44 mRNA and protein expression in primary breast carcinomas.
Histopathology
Berner HS,Suo Z,Risberg B,Villman K,Karlsson MG,Nesland JM
BMS125 was used in Flow Cytometry, Immunohistochemistry (Paraffin), Western Blot to examine the occurrence of CD44 isoforms in breast carcinomas and their role in predicting clinical outcome.
Sun Jun 01 00:00:00 EDT 2003